Vaccine Design pp 167-186 | Cite as

Analytic Vaccinology: Antibody-Driven Design of a Human Cytomegalovirus Subunit Vaccine

Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1403)

Abstract

Identification of the most relevant protective antigens has represented a considerable obstacle for the development of subunit vaccines against viral infections, including human cytomegalovirus (HCMV) infection. This chapter describes the method of analytic vaccinology, centered on the clonal analysis of human B cell response to HCMV, which represents an essential tool for assessing the impact of individual viral antigens in the antiviral antibody response. By providing key information on the immunogenicity and protective properties of the antibodies elicited by viral proteins, the analytic vaccinology method guides the selection of the most appropriate vaccine candidates. Here we discuss methodologies for the generation of human monoclonal antibodies from B cells of immune donors, antibody screening in in vitro assays of antigen binding and virus neutralization, and strategies of animal immunization useful for the preclinical evaluation of selected viral antigens. The approach of analytic vaccinology could be universally applied to the characterization of B-cell immune response against any virus of interest and ultimately used for vaccine development.

Key words

Virus Subunit vaccine Viral antigens Human monoclonal antibodies Screening Neutralizing Non-neutralizing 

References

  1. 1.
    Kabanova A, Perez L, Lilleri D et al (2014) Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. Proc Natl Acad Sci U S A 111:17965–17970CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Hangartner L, Zinkernagel RM, Hengartner H (2006) Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 6:231–243CrossRefPubMedGoogle Scholar
  3. 3.
    Corti D, Lanzavecchia A (2013) Broadly neutralizing antiviral antibodies. Annu Rev Immunol 31:705–742CrossRefPubMedGoogle Scholar
  4. 4.
    Griffiths PD, Stanton A, McCarrell E et al (2011) Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: A phase 2 randomised placebo-controlled trial. Lancet 377:1256–1263CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Lilleri D, Kabanova A, Revello MG et al (2013) Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gh/gl/pul128-130-131 complex during primary infection. PLoS One 8(3):e59863CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Traggiai E, Becker S, Subbarao K et al (2004) An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10:871–875CrossRefPubMedGoogle Scholar
  7. 7.
    Traggiai E (2012) Immortalization of human B Cells: analysis of B cell repertoire and production of human monoclonal antibodies. Methods Mol Biol 901:161–170CrossRefPubMedGoogle Scholar
  8. 8.
    Tiller T, Meffre E, Yurasov S et al (2008) Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods 329:112–124CrossRefPubMedGoogle Scholar
  9. 9.
    Smith K, Garman L, Wrammert J et al (2009) Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc 4:372–384CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Hahn G, Revello MG, Patrone M et al (2004) Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 78:10023–10033CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ryckman BJ, Rainish BL, Chase MC et al (2008) Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J Virol 82:60–70CrossRefPubMedGoogle Scholar
  12. 12.
    Ciferri C, Chandramouli S, Donnarumma D et al (2015) Structural and biochemical studies of HCMV gH/gL/gO and Pentamer reveal mutually exclusive cell entry complexes. Proc Natl Acad Sci 112:1767–1772CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Yamane Y, Furukawa T, Plotkin SA (1983) Supernatant virus release as a differentiating marker between low passage and vaccine strains of human cytomegalovirus. Vaccine 1:23–25CrossRefPubMedGoogle Scholar
  14. 14.
    Bowden RA, Slichter SJ, Sayers M et al (1995) A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 86:3598–3603PubMedGoogle Scholar
  15. 15.
    Lipson SM, Shepp DH, Match ME et al (2001) Cytomegalovirus infectivity in whole blood following leukocyte reduction by filtration. Am J Clin Pathol 116:52–55CrossRefPubMedGoogle Scholar
  16. 16.
    Gerna G, Percivalle E, Baldanti F et al (2000) Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events. J Virol 74:5629–5638CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Gerna G, Sarasini A, Patrone M et al (2008) Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J Gen Virol 89:853–865CrossRefPubMedGoogle Scholar
  18. 18.
    Krashias G, Simon AK, Wegmann F et al (2010) Potent adaptive immune responses induced against HIV-1 gp140 and influenza virus HA by a polyanionic carbomer. Vaccine 28:2482–2489CrossRefPubMedGoogle Scholar
  19. 19.
    Lai RP, Seaman MS, Tonks P et al (2012) Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to freund’s adjuvants. PLoS One 7(4):e35083CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Grazia Revello M, Baldanti F, Percivalle E et al (2001) In vitro selection of human cytomegalovirus variants unable to transfer virus and virus products from infected cells to polymorphonuclear leukocytes and to grow in endothelial cells. J Gen Virol 82:1429–1438CrossRefPubMedGoogle Scholar
  21. 21.
    Gerna G, Baldanti F, Percivalle E et al (2003) Early identification of human cytomegalovirus strains by the shell vial assay is prevented by a novel amino acid substitution in UL123 IE1 gene product. J Clin Microbiol 41:4494–4495CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Macagno A, Bernasconi NL, Vanzetta F et al (2010) Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH / gL / UL128-131A complex. J Virol 84:1005–1013CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of Life SciencesUniversity of SienaSienaItaly
  2. 2.Laboratori Sperimentali di RicercaArea Trapiantologica, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San MatteoPaviaItaly

Personalised recommendations